Bone Mineral Density Reductions After Tenofovir Disoproxil Fumarate Initiation and Changes in Phosphaturia: a Secondary Analysis of ACTG A5224s

Overview

Journal J Antimicrob Chemother

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2017 Apr 4

PMID 28369419

Citations 3

Authors

Samir K Gupta

Eunice Yeh

Douglas W Kitch

Todd T Brown

Charles S Venuto

Gene D Morse

Belinda Ha

Kathleen Melbourne

Grace A McComsey

Affiliations

Soon will be listed here.

Abstract

Background: It is unknown if the greater reductions in bone mineral density (BMD) associated with initiation of tenofovir disoproxil fumarate compared with abacavir in previously untreated HIV-infected participants in the ACTG A5224s clinical trial were associated with potentially worsening tenofovir-related phosphaturia.

Methods: We correlated changes in BMD at the hip and spine with changes in phosphaturia [transtubular reabsorption of phosphorus (TRP) and tubular maximum phosphate reabsorption per glomerular filtration rate (TmP/GFR)] from entry through week 96 in those initiating tenofovir ( n = 134) versus abacavir ( n = 135) with efavirenz or atazanavir/ritonavir in A5224s. We also correlated changes in BMD with tenofovir AUC measured between weeks 4 and 24.

Results: Changes in TRP and TmP/GFR through week 96 between the tenofovir and abacavir arms were not significantly different (both P ≥ 0.70) and did not differ with use of efavirenz versus atazanavir/ritonavir. There were no significant correlations between changes in either TRP or TmP/GFR and with either hip or spine BMD in the tenofovir arms. Tenofovir AUC was significantly correlated with changes in hip BMD, but not spine BMD, at week 24 ( r = -0.22, P = 0.028) and week 48 ( r = -0.26, P = 0.010), but not at week 96 ( r = -0.14, P = 0.18).

Conclusions: Changes in phosphaturia were not different between the tenofovir and abacavir arms in A5224s. Changes in hip and spine BMD with tenofovir were not related to changes in phosphaturia. However, tenofovir exposure was weakly associated with changes in hip BMD through week 48.

Citing Articles

Drug-Induced Hypophosphatemia: Current Insights.

Megapanou E, Florentin M, Milionis H, Elisaf M, Liamis G Drug Saf. 2019; 43(3):197-210.

PMID: 31776845 DOI: 10.1007/s40264-019-00888-1.

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

Biver E, Calmy A, Aubry-Rozier B, Birkhauser M, Bischoff-Ferrari H, Ferrari S Osteoporos Int. 2019; 30(5):1125-1135.

PMID: 30603840 DOI: 10.1007/s00198-018-4794-0.

Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.

Kalayjian R, Albert J, Cremers S, Gupta S, McComsey G, Klingman K AIDS. 2018; 32(17):2517-2524.

PMID: 30134291 PMC: 6230267. DOI: 10.1097/QAD.0000000000001995.

References

Horizon A, Joseph R, Liao Q, Ross S, Pakes G . Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS (Auckl). 2011; 3:53-9. PMC: 3218713. DOI: 10.2147/HIV.S15588. View

Masia M, Padilla S, Robledano C, Lopez N, Ramos J, Gutierrez F . Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses. 2011; 28(3):242-6. DOI: 10.1089/AID.2011.0052. View

Hamzah L, Tiraboschi J, Iveson H, Toby M, Mant C, Cason J . Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS). Antivir Ther. 2015; 21(4):287-96. DOI: 10.3851/IMP3000. View

Hamzah L, Samarawickrama A, Campbell L, Pope M, Burling K, Fisher M . Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients. AIDS. 2015; 29(14):1785-1792. PMC: 4878687. DOI: 10.1097/QAD.0000000000000760. View

Castillo A, Tarantal A, Watnik M, Martin R . Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J Orthop Res. 2002; 20(6):1185-9. DOI: 10.1016/S0736-0266(02)00074-8. View

Calmy A, Fux C, Norris R, Vallier N, Delhumeau C, Samaras K . Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009; 200(11):1746-54. DOI: 10.1086/644785. View

Gupta S . Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008; 22(2):99-103. DOI: 10.1089/apc.2007.0052. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Casado J, Santiuste C, Vazquez M, Banon S, Rosillo M, Gomez A . Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients. AIDS. 2016; 30(9):1423-31. DOI: 10.1097/QAD.0000000000001067. View

10.

McComsey G, Kitch D, Sax P, Tebas P, Tierney C, Jahed N . Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011; 53(2):185-96. PMC: 3165963. DOI: 10.1093/cid/cir324. View

11.

Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J . Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009; 23(6):689-96. DOI: 10.1097/QAD.0b013e3283262a64. View

12.

Maggi P, Montinaro V, Bellacosa C, Pietanza S, Volpe A, Graziano G . Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDS. 2011; 26(1):5-11. DOI: 10.1089/apc.2011.0185. View

13.

Kwan C, Eckhardt B, Baghdadi J, Aberg J . Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS Res Hum Retroviruses. 2012; 28(9):1025-32. PMC: 3423777. DOI: 10.1089/AID.2011.0325. View

14.

Andrade-Fuentes K, Mata-Marin J, Lopez-De Leon J, Manjarrez-Tellez B, Ramirez J, Gaytan-Martinez J . Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico. AIDS Patient Care STDS. 2014; 29(4):181-5. DOI: 10.1089/apc.2014.0134. View

15.

Sax P, Wohl D, Yin M, Post F, DeJesus E, Saag M . Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385(9987):2606-15. DOI: 10.1016/S0140-6736(15)60616-X. View

16.

Liu A, Vittinghoff E, Sellmeyer D, Irvin R, Mulligan K, Mayer K . Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011; 6(8):e23688. PMC: 3163584. DOI: 10.1371/journal.pone.0023688. View

17.

Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, Del Rio L . High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010; 24(18):2827-33. DOI: 10.1097/QAD.0b013e328340a28d. View

18.

Brown T, McComsey G . Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010; 15(3):425-9. DOI: 10.3851/IMP1502. View

19.

Ofotokun I, Titanji K, Vikulina T, Roser-Page S, Yamaguchi M, Zayzafoon M . Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun. 2015; 6:8282. PMC: 4580984. DOI: 10.1038/ncomms9282. View

20.

Womack J, Goulet J, Gibert C, Brandt C, Chang C, Gulanski B . Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011; 6(2):e17217. PMC: 3040233. DOI: 10.1371/journal.pone.0017217. View